Inducible CRISPR activation screen for interferon-stimulated genes identifies OAS1 as a SARS-CoV-2 restriction factor인터페론 자극 유전자에 대한 유도성 CRISPR 활성화 스크린은 OAS1을 SARS-CoV-2 제한 인자로 식별합니다Article Published on 2022-04-142022-09-11 Journal: PLoS Pathogens [Category] Coronavirus, COVID19(2023년), SARS, 유전자 메커니즘, 치료제, [키워드] Activation activities Antiviral Antiviral effect approach catalytic activity cDNA cell line complementary confounding effect CRISPR described exhibited experiments expression Factors function Genetic identify interferon interferon-stimulated gene interferon-stimulated genes interferons ISG ISGs mechanism OAS1 platform required respond restrict restriction factor Result SARS-CoV-2 specificity subset [DOI] 10.1371/journal.ppat.1010464 PMC 바로가기 [Article Type] Article
mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include OmicronCOVID-19에서 회복된 후 15개월 및 20개월 후 80세 여성에서 mRNA 백신 접종은 Omicron을 포함한 강력한 면역 및 항체 반응을 이끌어냅니다Article Published on 2022-04-122022-09-11 Journal: Cell Reports [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] ACE2 Activation acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 angiotensin angiotensin-converting enzyme 2 antibody Antibody binding antibody levels Antibody Response Antibody responses BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine BNT162b2 vaccine boost Cohort coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 CP: Microbiology cytokine doses elicit Genetic heavy chain high-risk population IgG IGHV IGHV clones immune Immune transcriptome Immunoglobulin Immunoglobulin G include individual Infection interferon Microbiology mRNA vaccination mRNA vaccine naïve individuals naive versus COVID-19-recovered individuals neutralization Neutralizing antibodies neutralizing antibody octogenarian. of BNT162b2 omicron PBMC receiving respiratory response RNA sequencing RNA-Seq robust SARS-CoV-2 SARS-CoV-2 spike-specific single dose sustained transcript Transcriptome vaccination Vaccine vaccine dose vulnerable population [DOI] 10.1016/j.celrep.2022.110680 PMC 바로가기 [Article Type] Article
STAT1 and Its Crucial Role in the Control of Viral InfectionsReview Published on 2022-04-072023-07-01 Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), SARS, [키워드] immune response interferon Stat1 viral infection [DOI] 10.3390/ijms23084095 PMC 바로가기 [Article Type] Review
SARS-CoV-2 nsp5 Exhibits Stronger Catalytic Activity and Interferon Antagonism than Its SARS-CoV OrthologArticle Published on 2022-04-072023-07-02 Journal: Journal of Virology [Category] COVID19(2023년), SARS, [키워드] 3C-like protease catalytic activity interferon NF-κB essential modulator (NEMO) nonstructural protein 5 (nsp5) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [DOI] 10.1128/jvi.00037-22 PMC 바로가기
Kinetics of immune responses to the AZD1222/Covishield vaccine with varying dose intervals in Sri Lankan individuals스리랑카 개인에서 다양한 투여 간격으로 AZD1222/Covishield 백신에 대한 면역 반응의 동역학Article Published on 2022-04-012022-09-11 Journal: Immunity, Inflammation and Disease [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] age antibodies antibody Antibody titer Antibody titers AZD1222 Cohort cohorts correlated COVID-19 dose dosing intervals dosing schedule ELISPOT ELISpot responses Ex vivo first dose group hemagglutination assay IFNγ immune response immune responses immunogenecity individual interferon interval Kinetics magnitude median no difference positive positive response post vaccination RBD Receptor-binding domain response responses SARS-CoV-2 virus second dose significantly significantly higher Spearman T cell T cell response T cells the RBD the receptor-binding domain the SARS-CoV-2 virus threshold total antibodies total antibody Vaccine Vaccines variants variants of concern virus VoC VOCs were assessed were measured [DOI] 10.1002/iid3.592 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial합성 다항원 변형 백시니아 바이러스 앙카라 기반 COVID-19 백신(COH04S1)의 안전성 및 면역원성: 공개 및 무작위 배정, 1상 시험Clinical Trial Published on 2022-04-012022-09-11 Journal: The Lancet. Microbe [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료법, [키워드] 95% CI Administered Adults Analysis Anxiety assigned baseline body-mass body-mass index boost Cellular responses center city Cohort Comprehensive Concentration COVID-19 vaccine development dose drug eight fatigue female Fever Fisher Fisher's exact test FIVE followed by foundation Future GRADE grade 3 Haematology healthy High dose High-dose Hope IgG immunogenicity immunological increase in initiated injection interferon interferon-γ Intramuscular injection less limit low dose low-dose medium dose modified vaccinia virus modified vaccinia virus Ankara Moss negative pregnancy test nine nucleocapsid nucleocapsid antigens nucleocapsid protein nucleocapsid-specific antibody Open-label outcome participant PCR test Phase 1 phase 1 trial Placebo placebo group plaque-forming unit plaque-forming units poxvirus pregnancy test Primary outcome provided randomised Randomly receive Registered reported risk Safety SARS-CoV-2 antibody SARS-CoV-2 neutralising antibodies SARS-CoV-2 neutralising antibody SARS-CoV-2 spike Secondary objectives secondary outcome secreting Seroconversion seroconversion rate seroconversion rates Seven severe adverse event severe adverse events Spike protein statistical T cell T cells T-cell responses titre Tolerability Trial troponin USA vaccination Vaccine Viral viral neutralisation was done was measured was tested [DOI] 10.1016/S2666-5247(22)00027-1 PMC 바로가기 [Article Type] Clinical Trial
Pandemic chilblains: Are they SARS-CoV-2-related or not?팬데믹 아동: SARS-CoV-2와 관련이 있습니까?Article Published on 2022-04-012022-09-11 Journal: Clinical immunology (Orlando, Fla.) [Category] COVID19(2023년), SARS, 치료기술, [키워드] affected anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody chilblain chilblains Cold containment measures coronavirus disease Coronavirus disease 2019 COVID-19 detectable eliminated environmental factor environmental factors Genome Hypothesis individual Initially interferon lesion lesions MOST no symptom no symptoms pandemic responses SARS-CoV-2 skin biopsies skin biopsy Support symptoms of COVID-19 Trigger Type type 1 interferon type I interferon virus [DOI] 10.1016/j.clim.2022.108984 PMC 바로가기 [Article Type] Article
Coronavirus Disease 2019 Messenger RNA Vaccine Immunogenicity in Immunosuppressed Individuals코로나바이러스 질병 2019 메신저 RNA 백신 면역억제된 개인의 면역원성Article Published on 2022-04-012022-09-11 Journal: The Journal of Infectious Diseases [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] 19 vaccine 2 acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition antibody Antibody Response Antibody responses binding CD4 CD8 T-cell coronavirus coronavirus disease Coronavirus disease 2019 CoV COVID COVID-19 COVID-19 mRNA Vaccination cross-reactivity function Immunocompromised immunocompromised individuals immunogenicity immunosuppressive increased mortality individual individuals Infection interferon interferon-γ lead messenger Messenger RNA mRNA mRNA vaccination mRNA vaccine Neutralizing reduce reduced regimen respiratory response RNA SARS SARS-CoV-2 SARS-CoV-2 variants severe acute respiratory syndrome Coronavirus T cells therapy These data vaccine immunogenicity Viral viral clearance Viral variants [DOI] 10.1093/infdis/jiab569 PMC 바로가기 [Article Type] Article
Tracing the SARS-CoV-2 infection on the ocular surface: Overview and preliminary corneoscleral transcriptome sequencing안구 표면의 SARS-CoV-2 감염 추적: 개요 및 예비 각막 공막 전사체 시퀀싱Article Published on 2022-04-012022-09-11 Journal: Experimental eye research [Category] COVID19(2023년), SARS, 유전자 메커니즘, 치료기술, [키워드] absence ADAMTS4 Analysis AQP5 associable caused Cluster Clusters component Cornea Corneal Corneoscleral ring COVID-19 CTRL Cytokines DEGs differentially expressed gene Differentially expressed genes Donor down-regulated gene down-regulated genes enrichment analysis Eye bank gene expression profile Gene ontology Genes genomic genomic RNA GO analysis GO term IL6 Illumina inactive indicated infected individual infected individuals Infection interferon interferon pathway ISG ISG15 ISGs Local Manifestations MMP1 modulation molecular mechanism molecular mechanisms ocular Ocular surface pathway PCA PCA analysis performed Perturbation positive Post-mortem principal Principal component principal component analysis proinflammatory cytokines Protective qRT-PCR RNA RNA-sequencing RSAD2 SARS-CoV-2 SARS-CoV-2 RNA several gene several genes Support tears the interferon the SARS-CoV-2 tissue tracing transcriptional Transcriptome transcriptome analysis transcriptome sequencing virus was performed [DOI] 10.1016/j.exer.2022.108975 PMC 바로가기 [Article Type] Article
Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study활성 치료 중인 고형 종양 환자에서 BNT162b2 항-SARS-CoV-2 백신 3차 접종 후 면역원성과 안전성: 전향적 코호트 연구Article Published on 2022-04-012022-09-11 Journal: ESMO open [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] active treatment acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration anti-SARS-CoV-2 antibody baseline BNT162b2 BNT162b2 anti-SARS-CoV-2 vaccine booster booster dose Cancer cancer patient Cancer patients cell-mediated immune cell-mediated immune response Concentration consecutive patient coronavirus coronavirus disease Coronavirus disease 2019 Course COVID-19 COVID-19 infection Delta dose effective Efficacy enrolled evaluated Gamma humoral IgG IgG antibody immunogenicity Immunoglobulin Immunoglobulin G interferon interferon gamma interferon-γ interquartile range IQR median Messenger RNA naïve naïve subject naïve subjects neutralization Neutralizing neutralizing antibody of BNT162b2 omicron Patient patients Preliminary data primary endpoint prospective cohort study quantified reached recruited Release respiratory SARS-CoV-2 SARS-CoV-2 vaccine serum severe acute respiratory syndrome Coronavirus significantly higher solid cancer solid tumor subject subjects the median the SARS-CoV-2 third dose Treatment Trigger Vaccine variant variants variants of concern VOCs were used whole blood sample wild-type strain [DOI] 10.1016/j.esmoop.2022.100458 PMC 바로가기 [Article Type] Article